Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy
. To find out more, read our
Privacy Policy
and our
Cookie Policy.